Invitation to a streamed lecture on Juvenile idiopathic arthritis – subtypes, epidemiology, prognosis, and treatment
Juvenile idiopathic arthritis (JIA) is an umbrella term entailing a heterogeneous group of inflammatory arthritides of unknown etiology, all defined by the presence of at least one inflamed joint persisting ≥ 6 weeks, beginning before 16 years of age and that cannot be explained by other causes such as infection or trauma.
Various sets of classification criteria have been used over the years, defining the different subtypes, the prevalence and incidence of which differ, as well as does the prognosis and treatment. Finally, the treatment options for JIA have increased over the years and therefore also the possibilities of achieving remission and improving outcome.
Novartis is happy to invite you to a streamed lecture on juvenile idiopathic arthritis – subtypes, epidemiology, prognosis, and treatment, with Doctor Elisabet Berthold, Consultant Rheumatology at the Department of Rheumatology at Skåne University Hospital in Lund, who is involved in research in juvenile idiopathic arthritis.
Participation in the meeting requires approval from the head of department.
Participation in the meeting is free of costs.
Welcome!
Thomas Mandl
Medical Lead Rheumatology
Novartis Sweden AB
